Fargo, N.D., based company increasing capacity to better serve
rapidly growing biotech industry.
Aldevron officially broke ground on its 14-acre campus expansion at its global headquarters in Fargo, North Dakota, August 19. Three buildings are planned, with construction of its next GMP manufacturing facility starting first.
“This is an exciting day for the company, our team, our clients and the patients that benefit from the work they do,” said Michael Chambers, co-founder and CEO of Aldevron. “We are growing to meet demands in the industry – demand for high quality biological products, demand for trusted partners to help solve the world’s largest health challenges, and demand for companies that support the evolution the biotech industry is experiencing. This campus will be innovative and dynamic, and will have a positive impact on drug development worldwide, from right here in Fargo.”
The campus will feature a second GMP manufacturing facility that more than quadruples its current capacity, an Administration and Client Experience Center and a Research and Development and Training Center.
Aldevron started on the campus of North Dakota State University in 1998 when John Ballantyne, now Chief Scientific Officer, and Chambers, both students at the time, saw an opportunity to create plasmid DNA for other research scientists. It now has more than 400 employees in three different locations including Fargo, Madison, WI, and Freiburg, Germany. The company recently announced it has a new majority interest partner, EQT, a leading private equity firm based in Europe.
“We are in an outstanding position for growth,” continued Chambers. “EQT will be an excellent partner as we continue to invest in our facilities, our people and our community.”
